Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 19, 2021
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
This filing details a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $103,750
- Net Proceeds: $100,000 (after fees and expenses)
- Interest Rate: 8% per annum (payable in cash or shares)
- Transaction Fees: $3,750 paid to the investor
- Use of Proceeds: General working capital
Note: The filing does not provide data on total revenue, profit, cash flow, margins, or aggregate debt levels.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc. ("Geneva") for a convertible promissory note. Material terms include:
- Maturity Date: August 19, 2022.
- Conversion Rights: Geneva may convert principal and interest into common stock starting February 16, 2022. The conversion price is set at 65% of the "Market Price" (a 35% discount), calculated as the average of the lowest three trading prices over the ten trading days prior to conversion.
- Conversion Limitation: Geneva is restricted from converting if it would result in beneficial ownership exceeding 4.99% of outstanding shares.
- Prepayment Penalties: The note may be prepaid within 180 days of issuance with escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon an event of default, the outstanding principal and accrued interest increase to 150% of the amount due ("Default Amount").
Outlook, Risks, and Contingencies
Management Commentary: The Company intends to utilize the net proceeds for general working capital purposes.
Risks and Contingencies:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Default Risk: Events of default include failure to maintain OTC market listing, failure to file SEC reports, insolvency, or failure to reserve shares for conversion. A default triggers a 50% penalty on the debt obligation.
- Liquidity Constraints: The Company covenants not to dispose of substantially all assets without consent, which could limit strategic flexibility.
- Penalty Fees: Failure to deliver shares upon conversion within three business days incurs a $1,000 per day penalty.
Investor Verification Checklist
- Verify the current number of outstanding shares to assess the potential dilution impact of the 4.99% conversion cap and the 35% discount rate.
- Confirm the Company's current cash position to evaluate its ability to meet the 8% interest obligation or prepayment premiums if required.
- Review the Company's recent SEC filings to ensure compliance with reporting requirements, as failure to file is an event of default.
- Check the current trading status of the Company's stock on OTC markets to ensure it remains listed, as delisting is an event of default.
- Examine the full text of the Securities Purchase Agreement (Exhibit 10.1) for additional covenants not summarized in the 8-K.